FDA clearance to commence Ph 2 trial of leronlimab in patients with R/R microsatellite stable CRC November 5, 2024
First Patient Dosed in Ph 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma October 29, 2024
Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma Presented October 29, 2024
Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma Presented October 29, 2024
VYLOY (zolbetuximab-clzb) Approved by US FDA for Treatment of Advanced Gastric and GEJ Cancer October 22, 2024
Positive CHMP Opinions for TEVIMBRA® as a 1L Treatment for Advanced/Metastatic Gastric or GEJ Cancer and Esophageal Squamous Cell Carcinoma October 22, 2024
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into 1L HCC Pivotal Trial October 15, 2024
Interim data from Ph 1 clinical study of misetionamide (GP-2250) in combination with gemcitabine in patients with pancreatic adenocarcinoma announced October 15, 2024
Key Progress and Upcoming Studies for Pelareorep Breast and Pancreatic Cancer Treatments Announced in Preparation for FDA Accelerated Approval Path October 8, 2024
Interim Ph 2 Data for GRANITE Neoantigen Targeting Immunotherapy in 1L Metastatic MSS CRC Announced October 8, 2024
FDA IND Clearance for ALE.P02, a Novel CLDN1-ADC for the Treatment of Squamous Cancers October 8, 2024
China NMPA approves Cadonilimab for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population October 8, 2024
Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or GEJ Cancer Expressing Claudin 18.2 October 2, 2024
EC approved toripalimab (LOQTORZI®) for the treatment of certain patients with mNPC and ESCC October 2, 2024
Anbogen Announces Drug Supply Collaboration with BeiGene to Evaluate Combination Therapy in Colorectal Cancer October 2, 2024
Significant New Data from Ph 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer Announced October 1, 2024
FAILED TRIAL: Ph 3 KEYFORM-007 trial of favezelimab + KEYTRUDA did not meet its primary endpoint of OS in patients with previously treated PD-L1+ve MSS mCRC October 1, 2024
FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers recommends a class-wide PD-L1 expression level cut-off across PD-1 inhibitors October 1, 2024
NDA Resubmitted to FDA for Camrelizumab + Rivoceranib for 1L Unresectable HCC Boosted by CARES-310 Leading OS Analysis October 1, 2024
